Interventions du FILO à l'ASH 2023 dans le domaine de la LAM

BIG-1

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Communication orale présentée par Mathilde HUNAULT-BERGER

Number: 967
Presenter: Hunault-Berger Mathilde
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for Treatment of AML
Time and Location: Monday, December 11, 2023: 4:30 PM-6:00 PM - San Diego Ballroom AB (Marriott Marquis San Diego Marina)

COVENIDAC

Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study

Poster présenté par Pierre PETERLIN

Number: 4261
Presenter: Pierre Peterlin
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
Time and Location: Monday, December 11, 2023: 6:00 PM-8:00 PM - Halls G-H (San Diego Convention Center)

FLAMVAL

Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study

Communication orale présentée par Pierre PETERLIN

Number: 975
Presenter: Pierre Peterlin
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Response Predictors to Targeted Therapies and Transplant
Time and Location: Monday, December 11, 2023: 4:30 PM-6:00 PM - Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)

 CPX-351-TA-SMP

CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia

Poster présenté par Sylvain GARCIAZ

Result Type: Paper
Number: 2917
Presenter: Sylvain Garciaz
Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Time and Location:
Sunday, December 10, 2023: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

MOSAIC

Association between Molecular Profile and Outcome after Intensive Chemotherapy in Patients > 60 Years with Adverse Cytogenetic Risk and/or Secondary Acute Myeloid Leukemia – a Filo Study

Poster présenté par Corentin ORVAIN

Number: 2851
Presenter: Corentin Orvain
Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
Time and Location: Sunday, December 10, 2023: 6:00 PM-8:00 PM - Halls G-H (San Diego Convention Center)

MOLAM

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1-Mutated Acute Myeloid Leukemia – a Filo Study

Communication orale présentée par Corentin ORVAIN

Number: 421
Presenter: Corentin Orvain
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease and Therapy Response
Time and Location: Sunday, December 10, 2023: 9:30 AM-11:00 AM- Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)

STOP-VEN

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Communication orale présentée par Sylvain GARCIAZ

Number: 161
Presenter: Sylvain Garciaz
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Uses of Approved Therapeutic Agents
Time and Location: Saturday, December 9, 2023: 2:00 PM-3:30 PM - Room 6A (San Diego Convention Center)

BIG-1

Clonal Dynamics of FLT3-ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Communication orale présentée par Romane JOUDINAUD

Result Type: Paper
Number: 976
Presenter: Romane Joudinaud
Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Response Predictors to Targeted Therapies and Transplant
Time and Location:
Monday, December 11, 2023: 4:30 PM-6:00 PM
Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)

MIDOLA

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Poster présenté par Gaspar ASPAS REQUENA

Result Type: Paper
Number: 2864
Presenter: Gaspar Aspas Requena
Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
Time and Location:
Sunday, December 10, 2023: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)